Skip to main content

Closed

CTMX: CytomX Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+36.4% / yr

Operating margin-181.9%

ROIC-19.7%

Financially safe

Stretched

Debt / equity0.01×

Interest coverage0.0×

Current ratio10.38×

CytomX Therapeutics, Inc.

CTMXNASDAQ Global Select·USD·Closed

CytomX Therapeutics, Inc.

CTMXNASDAQ·USD·Closed

$3.10

−5.49%

$3.10

−$0.18 (5.49%)

52W Range

21thpctl

Volume

0.84×avg

Mkt Cap

498.55MUSD

P/E

-8.6TTM

Div Yield

–ann

52W Range

21thpctl

Volume

0.84×avg

Market Cap

498.55MUSD

P/E Ratio

-8.6TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings